Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CB-011
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Caribou Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Caribou Biosciences and ProMab Biotechnologies Inks Agreement
Details : Caribou intends to utilize this scFv in the development of its CB-011 program, an allogeneic CAR-T therapy targeting BCMA-positive tumors including multiple myeloma.
Product Name : CB-011
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 19, 2020
Lead Product(s) : CB-011
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Caribou Biosciences
Deal Size : Undisclosed
Deal Type : Agreement